Research programme: bi-specific recombinant fusion cancer vaccines - In3Bio
Latest Information Update: 24 Mar 2021
Price :
$50 *
At a glance
- Originator In3Bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Mar 2021 Research programme: Bi-specific recombinant fusion proteins - In3Bio is available for licensing as of 09 Mar 2021. (https://in3bio.com/technology-platform-3/)
- 09 Mar 2021 Preclinical trials in Cancer in United Kingdom (unspecified route) prior to March 2021 (In3Bio pipeline, March 2021)